Sagimet Biosciences Inc. director Jennifer Jarrett reported a grant of stock options on Series A Common Stock. She received options for 39,567 shares at an exercise price of $6.48 per share, all held as a direct derivative position following the transaction.
According to the terms, the shares underlying this option will vest and become exercisable in twelve equal monthly installments following June 12, 2026, conditioned on her continued service on each vesting date. The option expires on June 11, 2036, providing a long-dated equity incentive aligned with her board role.
Sagimet Biosciences Inc. director Elizabeth A. Grammer received a grant of stock options covering 39,567 shares of Series A Common Stock. The options have an exercise price of $6.48 per share and expire on June 11, 2036.
The shares underlying this option are scheduled to vest in twelve equal monthly installments following June 12, 2026, contingent on her continued service on each vesting date. This is a compensation-related award and does not reflect any open-market buying or selling of Sagimet stock.
Sagimet Biosciences Inc. granted director Kemble George a stock option covering 39,567 shares of Series A Common Stock at an exercise price of $6.48 per share. The option expires on June 11, 2036 and represents 39,567 derivative shares held after this grant.
According to the award terms, the shares underlying this option vest in twelve equal monthly installments following June 12, 2026, conditioned on his continued service on each vesting date.
Sagimet Biosciences Inc. director Anne M. Phillips received a grant of stock options covering 39,567 shares of Series A Common Stock at an exercise price of $6.48 per share. These options were awarded as compensation and are held directly.
The options vest and become exercisable in twelve equal monthly installments following June 12, 2026, contingent on her continued service on each vesting date. Following this grant, she holds stock options for 39,567 underlying shares, all from this award.
Sagimet Biosciences Inc. reported a Board change and the results of its 2026 Annual Meeting of Stockholders. Director Tim Walbert resigned from the Board effective June 12, 2026, citing other commitments and no disagreements with the company.
At the virtual annual meeting, held June 12, 2026, with 32,017,613 Series A common shares outstanding as of the April 17, 2026 record date, stockholders elected Class III directors Jennifer Jarrett, Anne Phillips, M.D., David Happel and George Kemble, Ph.D. to serve until the 2029 annual meeting, and ratified KPMG LLP as independent registered public accounting firm for the 2026 fiscal year.
Sagimet Biosciences Inc. reported new long-term equity awards for three senior officers. On May 28, 2026, the company granted stock options and performance-based restricted stock units (PSUs) under its 2023 Stock Option and Incentive Plan to its CEO, CFO, and Chief Legal and Administrative Officer.
CEO David Happel received 300,000 options and 300,000 PSUs, CFO Thierry Chauche received 50,000 options and 50,000 PSUs, and Chief Legal and Administrative Officer Elizabeth Rozek received 100,000 options and 100,000 PSUs. Each option has an exercise price of $7.27 per share, matching the Series A common stock closing price on the grant date, and vests in equal installments over 48 months.
The PSUs will be earned based on the company’s achievement of specified regulatory milestones. For each officer, one-third of the earned PSUs will vest on the date the Compensation Committee determines that these milestones were achieved, with the remaining two-thirds vesting in two equal installments on the first and second anniversaries of that determination date.
Sagimet Biosciences granted its Chief Financial Officer, Thierry Chauche, a stock option to acquire 50,000 shares of Series A Common Stock. The option has a $7.27 per-share exercise price and expires on May 27, 2036.
According to the filing, these options vest in 48 equal monthly installments beginning after May 28, 2026, contingent on his continued service. Following this grant, Chauche holds 50,000 stock options directly, reflecting routine equity-based compensation rather than an open-market transaction.
Sagimet Biosciences Inc. reported that Chief Medical Officer Andreas Grauer received a grant of stock options. The grant covers 35,000 Stock Options (Right to Buy), each exercisable for one share of Series A Common Stock at an exercise price of $7.27 per share.
The options vest in forty-eight equal monthly installments starting on May 28, 2026, conditioned on Dr. Grauer’s continued service on each vesting date. Following this grant, the filing shows Dr. Grauer directly holding 35,000 options under this award.
Sagimet Biosciences Inc. reported that Chief Legal & Admin. Officer Elizabeth Rozek received a grant of stock options as part of her compensation. She was awarded 100,000 stock options, each giving the right to buy one share of Series A common stock at an exercise price of $7.27 per share. These options expire on May 27, 2036. According to the terms, the shares underlying this option will vest in 48 equal monthly installments beginning after May 28, 2026, contingent on her continued service, and her reported derivative holdings after this grant total 100,000 options.
Sagimet Biosciences Inc. reported that President & CEO David Happel received a grant of stock options covering 300,000 shares of Series A common stock. The options have an exercise price of $7.27 per share and were awarded at no cost to him.
These options vest in forty-eight equal monthly installments starting on May 28, 2026, contingent on his continued service. After this grant, he holds options on 300,000 shares according to the filing. The transaction reflects equity-based compensation rather than an open-market purchase or sale.